Natural Killer Cell and Activated T-Cell Profile/IL-2r

Natural Killer Cell and Activated T-Cell Profile/IL-2r

Number

502500

CPT

86356; 86357; 86359

Synonyms

CD25 ; Interleukin-2 Receptor ; TAC Antigen

Test Includes

Percentage CD3⁺; absolute CD3⁺; percentage CD3⁺CD25⁺ (IL-2 receptor); absolute CD3⁺CD25⁺; percentage CD3^-CD56⁺ (NK); total CD3^-CD56⁺ (NK); CBC with differential; total lymphocyte count

Special Instructions

State date and time of collection on the request form and on specimen.

Specimen

Whole blood

Volume

7 mL EDTA whole blood and 7 mL ACD-A whole blood

Container

Lavender-top (EDTA) tube and yellow-top (ACD-A) tube

Collection

To preserve cellular viability, collect specimen so it will arrive in the laboratory Monday through Friday and within 24 hours of collection. Please indicate date and time of venipuncture on the tube(s) and on the request form.

Storage Instructions

Maintain specimen at room temperature. Do not freeze or refrigerate.

Causes for Rejection

Hemolysis; specimen refrigerated or frozen; clotted specimen; contaminated specimen

Reference Interval

Reference intervals for adults have been established by the laboratory. See table. Adult Reference Intervals for Lymphocyte Immunophenotyping

CD	95% Confidence Interval
	Percentage		Cells/mm³
	Minimum	Maximum	Minimum	Maximum
CD3⁺	58	86	622	2402
CD3⁺CD25⁺	5	26	79	535
CD3^-CD56⁺	1	19	24	406

Use

Assess changes in T-lymphocyte surface markers that may indicate immune stimulation

Limitations

This procedure may be considered by Medicare and other carriers as investigational and, therefore, may not be payable as a covered benefit for patients.

Methodology

Flow cytometry

Additional Information

Natural killer (NK) cells are large granular lymphocytes that mediate MHC-unrestricted cytotoxicity against virus-infected and malignant cells and manufacture a number of cytokines following stimulation of the immune system.

The combination of IL-2 and T-cell markers can be used to assess the state of activation of T cells. NK cells are responsible for the destruction of virally infected cells, tumor cells, and antibody-dependent cellular cytotoxicity.

References

Caligiuri M, Murray C, Buchwald D, et al, “Phenotypic and Functional Deficiency of Natural Killer Cells in Patients With Chronic Fatigue Syndrome,” J Immunol, 1987, 139(10):3306-13.

Landay AL, Jessop C, Lennette ET, et al, “Chronic Fatigue Syndrome: Clinical Condition Associated With Immune Activation,” Lancet, 1991, 338(8769):707-12.

Lanier L and Jackson A, “Monoclonal Antibodies: Differentiation Antigens Expressed on Leukocytes,” Manual of Clinical Laboratory Immunology, 4th ed, Chapter 23, Rose N, deMacario E, Fahey J, et al, eds, Washington, DC: ASM Press, 1992.

Rich RR, et al, ed, Clinical Immunology: Principles and Practice, Chapter 87, St Louis, MO: Mosby-Year Book, 1996.